630P Apalutamide for non-metastatic castration resistant prostate cancer (nmCRPC): A comparison of real-life experience from an international named patient program (NPP) vs the prior phase III clinical study

Autor:	K. Hatzimouratidis, I. Sayers, Giuseppe Procopio, M. Saad, T.J. Schnöller, Angela Lopez-Gitlitz, Heather Payne, Martin Bögemann, Joris Diels, O. Shatkovskaya, J. McCaffrey, L. Antoni, Suneel Mundle, M. Santoni, Susan Feyerabend, A. Manduley, M. Kase, M. Bulbul, Sharon Anne McCarthy, Geneviève Pissart
Rok vydání:	2020
Předmět:	Oncology medicine.medical_specialty business.industry Apalutamide Hematology Castration resistant medicine.disease Clinical study chemistry.chemical_compound Prostate cancer chemistry Internal medicine medicine Non metastatic business
Zdroj:	Annals of Oncology. 31:S520
ISSN:	0923-7534
DOI:	10.1016/j.annonc.2020.08.889
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::0eaa56a9f42dd715f2f1c7f996becfad https://doi.org/10.1016/j.annonc.2020.08.889 Zobrazit plný text záznamu